Xianzhi Mao
Idera Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Angiogenesis and VEGF in Cancer, DNA Repair Mechanisms, RNA Interference and Gene Delivery, Advanced biosensing and bioanalysis techniques, Immunotherapy and Immune Responses
Most-Cited Works
- → Discovery of a Small Molecule Insulin Mimetic with Antidiabetic Activity in Mice(1999)454 cited
- → Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate(1998)443 cited
- → Evaluation of Efficacy, Biodistribution, and Inflammation for a Potent siRNA Nanoparticle: Effect of Dexamethasone Co-treatment(2009)206 cited
- → Vascular Endothelial Growth Factor Receptor KDR Tyrosine Kinase Activity Is Increased by Autophosphorylation of Two Activation Loop Tyrosine Residues(1999)133 cited
- → Development of thioquinazolinones, allosteric Chk1 kinase inhibitors(2008)74 cited
- → Mechanistically Probing Lipid-siRNA Nanoparticle-associated Toxicities Identifies Jak Inhibitors Effective in Mitigating Multifaceted Toxic Responses(2010)72 cited
- → Dynamic Contrast-Enhanced MRI Measurements of Passive Permeability through Blood Retinal Barrier in Diabetic Rats(2004)65 cited
- → Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy(2018)64 cited
- → Potent N-(1,3-Thiazol-2-yl)pyridin-2-amine Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors with Excellent Pharmacokinetics and Low Affinity for the hERG Ion Channel(2004)60 cited
- → 3-(Indol-2-yl)indazoles as Chek1 kinase inhibitors: Optimization of potency and selectivity via substitution at C6(2006)46 cited